sec filing
GR
NASDAQ · GRCE
Grace Therapeutics, Inc.
Healthcare · Biotechnology
$2.10
Down-$0.04 (-1.87%)
Updated Sep 6, 2026, 9:42 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 47.49M
- P/E ratio
- -6.84
- Dividend yield
- 0.00%
- 52-week range
- $1.79 – $5.18
- Volume
- 186.77K
- Avg. volume
- 65.65K
Price performance
GRCE price history
1M range · 20 trading sessions · Daily adjusted prices
GRCE closed at $2.10 after 20 trading sessions, down 0.47% for the selected period.
- Last close
- $2.10
- Period change
- -0.47%
- Period low
- $2.07
- Period high
- $2.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $2.12 | $2.1899 | $2.08 | $2.10 | 186.77K |
| Sep 3, 2026 | $2.15 | $2.20 | $2.07 | $2.14 | 159.23K |
| Sep 2, 2026 | $2.19 | $2.19 | $2.0969 | $2.14 | 48.98K |
| Sep 1, 2026 | $2.09 | $2.14 | $2.07 | $2.10 | 78.97K |
| Aug 31, 2026 | $2.1012 | $2.14 | $2.07 | $2.13 | 117.31K |
| Aug 28, 2026 | $2.16 | $2.16 | $2.12 | $2.12 | 66.11K |
| Aug 27, 2026 | $2.10 | $2.18 | $2.10 | $2.16 | 82.27K |
| Aug 26, 2026 | $2.20 | $2.20 | $2.14 | $2.15 | 22.21K |
| Aug 25, 2026 | $2.18 | $2.22 | $2.18 | $2.20 | 94.44K |
| Aug 24, 2026 | $2.23 | $2.23 | $2.13 | $2.18 | 86.6K |
| Aug 21, 2026 | $2.15 | $2.2299 | $2.15 | $2.20 | 75.91K |
| Aug 20, 2026 | $2.19 | $2.24 | $2.10 | $2.14 | 54.72K |
| Aug 19, 2026 | $2.16 | $2.21 | $2.1509 | $2.20 | 159.76K |
| Aug 18, 2026 | $2.17 | $2.17 | $2.04 | $2.13 | 103.94K |
| Aug 17, 2026 | $2.19 | $2.25 | $2.15 | $2.16 | 99.36K |
| Aug 14, 2026 | $2.06 | $2.19 | $2.02 | $2.16 | 397.81K |
| Aug 13, 2026 | $2.10 | $2.13 | $2.058 | $2.07 | 193.83K |
| Aug 12, 2026 | $2.13 | $2.13 | $2.06 | $2.10 | 121.84K |
| Aug 11, 2026 | $2.10 | $2.13 | $2.08 | $2.12 | 97.76K |
| Aug 10, 2026 | $2.13 | $2.16 | $2.075 | $2.11 | 184.32K |
Latest GRCE news
The latest Smart Investors Daily articles mentioning GRCE.
Stock researchMarket Activity · Insider Trades
Loading stock research…

